Drug updated on 4/18/2024
| Dosage Form | Capsule (oral; 100 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Summary
- Fedratinib (Inrebic) is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis and exhibits comparable efficacy to other Janus kinase inhibitors such as momelotinib and ruxolitinib in reducing spleen volume and alleviating total symptom scores.
- Two studies were reviewed, which provided information about Inrebic's comparison with other JAK inhibitors for the treatment of myelofibrosis.
- The studies suggest that fedratinib has a distinctive advantage over some counterparts due to lesser toxicity on platelets, indicating its favorable profile for individuals concerned about thrombocytopenia.
- When considering first-line therapy, fedratinib, along with momelotinib and ruxolitinib, are viable options; however, there may be potential benefits of selecting fedratinib or momelotinib for individuals at risk of anemia and thrombocytopenia, respectively.
- As part of second-line therapy considerations, pacritinib appears less effective than ruxolitinib but shows promise post-ruxolitinib exposure, while fedratinib remains a critical option across the spectrum.
- Fedratinib also falls under JAK inhibitors, which have been associated with a significantly reduced risk of mortality among hospitalized COVID-19 patients, although further details would be required to understand its specific contribution within this context.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Inrebic (fedratinib) Prescribing Information. | 2023 | Bristol-Myers Squibb, New York, NY |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis. | 2021 | Blood Cancer Journal |
| The use of Janus kinase inhibitors in hospitalized patients with COVID-19: systematic review and meta-analysis. | 2021 | Clinical Epidemiology and Global Health |